Pharma Pulse: J&J’s $1B Cell Therapy Hub and Hims & Hers’ Global Expansion

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• Johnson & Johnson has announced a landmark $1 billion investment in a next-generation cell therapy manufacturing facility in Pennsylvania’s Montgomery County. This site is expected to become a cornerstone of J&J’s broader $55 billion US strategy that’s focused on manufacturing, R&D, and technology; it will also support 500 skilled biomanufacturing jobs.
• Meanwhile, telehealth giant Hims & Hers is scaling across borders with a $1.15 billion acquisition of the Australian digital health platform Eucalyptus. The deal gives Hims immediate access to the Australian market—it already has leading weight-loss program Juniper as part of its portfolio. With Eucalyptus generating over $450 million in annual revenue, Hims & Hers is positioning itself as a global leader in personalized, consumer-first care.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.